Target Name: ELAPOR1
NCBI ID: G57535
Review Report on ELAPOR1 Target / Biomarker Content of Review Report on ELAPOR1 Target / Biomarker
ELAPOR1
Other Name(s): Endosome/lysosome-associated apoptosis and autophagy regulator 1 isoform 1 | EIG121 | Hypothetical protein LOC57535 | endosome-lysosome associated apoptosis and autophagy regulator 1 | ELAPOR1 variant 1 | Endosome/lysosome-associated apoptosis and autophagy regulator 1 isoform 2 | Endosome/lysosome-associated apoptosis and autophagy regulator 1 | Estrogen-induced gene 121 protein | Endosome-lysosome associated apoptosis and autophagy regulator 1, transcript variant 1 | Endosome-lysosome associated apoptosis and autophagy regulator 1, transcript variant 2 | ELAPOR1 variant 2 | ELAP1_HUMAN | KIAA1324 | Maba1 | estrogen-induced gene 121 protein | maba1

ELAPOR1: A Potential Drug Target and Biomarker for Apoptosis and Autophagy

Apoptosis and autophagy are essential cellular processes that play a crucial role in tissue homeostasis and are tightly regulated to maintain cellular health. Disruptions in these processes can lead to a wide range of diseases, including cancer, neurodegenerative diseases, and developmental disorders. The protein ELAPOR1, also known as Endosome/lysosome-associated apoptosis and autophagy regulator 1 isoform 1, has been identified as a potential drug target and biomarker for these diseases due to its unique function in regulating apoptosis and autophagy.

ELAPOR1: Structure and Function

ELAPOR1 is a 22kDa protein that is expressed in a variety of tissues, including brain, heart, and gastrointestinal tract. It is localized to the endosome, a specialized organelle that plays a crucial role in the delivery and processing of viruses and other foreign particles, as well as the degradation of damaged or dysfunctional cells. ELAPOR1 is involved in the regulation of several cellular processes that are critical for maintaining cellular homeostasis, including autophagy, apoptosis, and the regulation of cell cycle progression.

In addition to its role in regulating autophagy, ELAPOR1 is also involved in the regulation of apoptosis, which is the process by which cells respond to environmental stressors, such as DNA damage or exposure to toxins, by undergoing programmed cell death. In response to these stressors, ELAPOR1 helps to induce apoptosis by activating several transcription factors, including Bcl-2, which plays a critical role in the regulation of apoptosis.

ELAPOR1 also helps to regulate the regulation of cell cycle progression by preventing the formation of stable cell-cell junctions, which are thought to play a role in the development of cancer. Additionally, ELAPOR1 is involved in the regulation of inflammation, which is a critical aspect of tissue homeostasis and is tightly regulated to prevent excessive immune response.

Mutations in ELAPOR1 have been identified as a contributing factor to a wide range of diseases, including neurodegenerative diseases, cancer, and developmental disorders. These mutations have been shown to disrupt the regulation of autophagy and apoptosis, leading to an imbalance in cellular homeostasis.

ELAPOR1 as a Drug Target

The potential drug target for ELAPOR1 is based on its role in regulating apoptosis and autophagy, as well as its involvement in the regulation of cell cycle progression and inflammation. Drugs that target ELAPOR1 have the potential to treat a wide range of diseases, including neurodegenerative diseases, cancer, and developmental disorders.

One approach to targeting ELAPOR1 is to use small molecules that can inhibit its activity. These small molecules can be designed to interact with specific domains of ELAPOR1, such as its catalytic active site or its binding interface with other proteins. By inhibiting ELAPOR1's activity, these drugs can prevent it from regulating apoptosis and autophagy, which can lead to the development of diseases associated with these processes.

Another approach to targeting ELAPOR1 is to use antibodies that recognize and specifically target its protein. These antibodies can be used to treat diseases associated with ELAPOR1 activity, such as neurodegenerative diseases, cancer, and developmental disorders.

ELAPOR1 as a Biomarker

ELAPOR1 can also be used as a biomarker for a variety of diseases, including neurodegenerative diseases, cancer, and developmental disorders. The regulation of autophagy and apoptosis is critical for the maintenance of cellular homeostasis, and disruptions in these processes can lead to the development of diseases. Therefore, the regulation of ELAPOR1 activity can be used as a biomarker for these diseases.

ELAPOR1 levels can be measured in a variety of tissues, including brain, heart, and gastrointestinal tract, using techniques such as Western blotting or immunofluorescence. The levels of ELAPOR1 can be used to monitor the effectiveness of drugs that target its activity, such as those that inhibit ELAPOR1's catalytic activity or those that specifically target its binding interface with other proteins.

Conclusion

ELAPOR1 is a protein that plays a critical role in regulating apoptosis and autophagy, as well as the regulation of cell cycle progression and inflammation. It is also involved in the regulation of cellular homeostasis and is a potential drug target and biomarker for a wide range of diseases. Further research is needed to fully understand the function of ELAPOR1 and its potential as a drug and biomarker.

Protein Name: Endosome-lysosome Associated Apoptosis And Autophagy Regulator 1

Functions: May protect cells from cell death by inducing cytosolic vacuolization and up-regulating the autophagy pathway (PubMed:21072319). May play a role in apoptosis and cell proliferation through its interaction with HSPA5 (PubMed:26045166)

The "ELAPOR1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ELAPOR1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

ELAPOR2 | Elastase | ELAVL1 | ELAVL2 | ELAVL3 | ELAVL4 | ELDR | ELF1 | ELF2 | ELF2P4 | ELF3 | ELF3-AS1 | ELF4 | ELF5 | ELFN1 | ELFN1-AS1 | ELFN2 | ELK1 | ELK2AP | ELK3 | ELK4 | ELL | ELL2 | ELL2P1 | ELL3 | ELMO1 | ELMO2 | ELMO3 | ELMOD1 | ELMOD2 | ELMOD3 | ELN | ELOA | ELOA-AS1 | ELOA2 | ELOA3BP | ELOA3DP | ELOA3P | ELOB | ELOC | ELOF1 | Elongation Factor 1 Complex | Elongation of very long chain fatty acids protein | Elongin (SIII) complex | ELOVL1 | ELOVL2 | ELOVL2-AS1 | ELOVL3 | ELOVL4 | ELOVL5 | ELOVL6 | ELOVL7 | ELP1 | ELP2 | ELP3 | ELP4 | ELP5 | ELP6 | ELSPBP1 | EMB | EMBP1 | EMC1 | EMC1-AS1 | EMC10 | EMC2 | EMC3 | EMC3-AS1 | EMC4 | EMC6 | EMC7 | EMC8 | EMC9 | EMCN | EMD | EME1 | EME2 | EMG1 | EMID1 | EMILIN1 | EMILIN2 | EML1 | EML2 | EML2-AS1 | EML3 | EML4 | EML4-AS1 | EML5 | EML6 | EMP1 | EMP2 | EMP2P1 | EMP3 | EMSLR | EMSY | EMX1 | EMX2 | EMX2OS | EN1 | EN2 | ENAH